Cargando…

RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR

Small cell lung cancer (SCLC) is an aggressive cancer that represents ~15% of all lung cancers. Currently there are no targeted therapies to treat SCLC. Our genomic analysis of a metastatic SCLC cohort identified recurrent RICTOR amplification. Here, we examine the translational potential of this ob...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sakre, Nneha, Wildey, Gary, Behtaj, Mohadese, Kresak, Adam, Yang, Michael, Fu, Pingfu, Dowlati, Afshin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351607/ https://www.ncbi.nlm.nih.gov/pubmed/27863413 http://dx.doi.org/10.18632/oncotarget.13362

Ejemplares similares

Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer
por: McColl, Karen, et al.
Publicado: (2017)

Post‐transcriptional regulation of PIAS3 expression by miR‐18a in malignant mesothelioma
por: He, Tian, et al.
Publicado: (2018)

PIAS3 expression in squamous cell lung cancer is low and predicts overall survival
por: Abbas, Rime, et al.
Publicado: (2015)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

Pharmacogenomic Approach to Identify Drug Sensitivity in Small-Cell Lung Cancer
por: Wildey, Gary, et al.
Publicado: (2014)

Identification of RUNX1T1 as a potential epigenetic modifier in small‐cell lung cancer
por: He, Tian, et al.
Publicado: (2020)

Proximity labeling of endogenous RICTOR identifies mTOR complex 2 regulation by ADP ribosylation factor ARF1
por: Luciano, Amelia K., et al.
Publicado: (2022)

Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer
por: Bhateja, Priyanka, et al.
Publicado: (2019)

Novel RICTOR amplification harbouring entities: FISH validation of RICTOR amplification in tumour tissue after next-generation sequencing
por: Sztankovics, Dániel, et al.
Publicado: (2023)

Interaction between NBS1 and the mTOR/Rictor/SIN1 Complex through Specific Domains
por: Wang, Jian-Qiu, et al.
Publicado: (2013)

Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma
por: Benavides-Serrato, Angelica, et al.
Publicado: (2017)

The role of RICTOR amplification in targeted therapy and drug resistance
por: Zhao, Deze, et al.
Publicado: (2020)

Correction: Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma
por: Benavides-Serrato, Angelica, et al.
Publicado: (2019)

Retraction: Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma
Publicado: (2023)

Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer
por: Ruder, Dennis, et al.
Publicado: (2018)

CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancer
por: Lindner, Daniel J., et al.
Publicado: (2020)

RICTOR/mTORC2 affects tumorigenesis and therapeutic efficacy of mTOR inhibitors in esophageal squamous cell carcinoma
por: Lu, Zhaoming, et al.
Publicado: (2020)

Pharmacological vitamin C inhibits mTOR signaling and tumor growth by degrading Rictor and inducing HMOX1 expression
por: Qin, Senlin, et al.
Publicado: (2023)

Tumor-suppressive microRNA-218 inhibits tumor angiogenesis via targeting the mTOR component RICTOR in prostate cancer
por: Guan, Bing, et al.
Publicado: (2016)

Platelet-derived growth factor-induced Akt phosphorylation requires mTOR/Rictor and phospholipase C-γ1, whereas S6 phosphorylation depends on mTOR/Raptor and phospholipase D
por: Razmara, Masoud, et al.
Publicado: (2013)

Correction: Tumor-suppressive microRNA-218 inhibits tumor angiogenesis via targeting the mTOR component RICTOR in prostate cancer
por: Guan, Bing, et al.
Publicado: (2022)

A detailed smoking history and determination of MYC status predict response to checkpoint inhibitors in advanced non-small cell lung cancer
por: Chiu, Michelle, et al.
Publicado: (2020)

A shift of the TOR adaptor from Rictor towards Raptor by semaphorin in C. elegans
por: Nukazuka, Akira, et al.
Publicado: (2011)

Novel Non-Invasive Radiomic Signature on CT Scans Predicts Response to Platinum-Based Chemotherapy and Is Prognostic of Overall Survival in Small Cell Lung Cancer
por: Jain, Prantesh, et al.
Publicado: (2021)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Dietary protein sources differentially affect microbiota, mTOR activity and transcription of mTOR signaling pathways in the small intestine
por: Kar, Soumya K., et al.
Publicado: (2017)

The role of RICTOR downstream of receptor tyrosine kinase in cancers
por: Jebali, Ahlem, et al.
Publicado: (2018)

Rictor maintains endothelial integrity under shear stress
por: Li, Hui, et al.
Publicado: (2022)

Targeting ganglioneuromas with mTOR inhibitors
por: Tao, Ting, et al.
Publicado: (2021)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Synergistic killing of human small cell lung cancer cells by the Bcl-2-inositol 1,4,5-trisphosphate receptor disruptor BIRD-2 and the BH3-mimetic ABT-263
por: Greenberg, E F, et al.
Publicado: (2015)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR
por: Villar, Victor H., et al.
Publicado: (2017)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

The Prognostic Role of mTOR and P-mTOR for Survival in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Li, Lei, et al.
Publicado: (2015)

The clinicopathological and prognostic significance of mTOR and p-mTOR expression in patients with non-small cell lung cancer: A meta-analysis
por: Qiu, Weiwei, et al.
Publicado: (2022)

Rictor Is Required for Early B Cell Development in Bone Marrow
por: Zhang, Yingchi, et al.
Publicado: (2014)

Conditional Astroglial Rictor Overexpression Induces Malignant Glioma in Mice
por: Bashir, Tariq, et al.
Publicado: (2012)

Rictor regulates cell migration by suppressing RhoGDI2
por: Agarwal, Nitin K., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_breu1589ddse9jolmqmmlp20d6